Last edition
News about "efzimfotase alfa"
Alexion Reports Positive Phase 3 Results for Efzimfotase Alfa in Children with Rare Bone Disease
Alexion, AstraZeneca Rare Disease, has announced positive Phase 3 results for investigational enzyme replacement therapy efzimfotase alfa in children with HPP. The therapy demonstrated significant improvements in bone health and physical function, reinforcing its potential as a next-generation treatment for the rare inherited metabolic disorder.
Efzimfotase Alfa | 30/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy